Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei
- PMID: 22359216
- DOI: 10.1007/s10637-012-9797-7
Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei
Abstract
Pseudomyxoma peritonei is a disease characterised by the accumulation of mucinous ascites. Thus far, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been shown to be effective at eradicating disease. Chemotherapy has been less effective, providing disease stabilization but not demonstrating significant treatment responses. Mucolytic is a potential class of drug that may be exploited in the chemical management of this disease. A variety of potential mucolytic agents are explored in this review providing evidence of basic biochemical evidence of its efficacy with potential translational application.
Similar articles
-
[Pseudomyxoma peritonei; a rare tumour that can be treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].Ned Tijdschr Geneeskd. 2007 Feb 17;151(7):418-23. Ned Tijdschr Geneeskd. 2007. PMID: 17343142 Dutch.
-
Mucolysis by ascorbic acid and hydrogen peroxide on compact mucin secreted in pseudomyxoma peritonei.J Surg Res. 2012 May 15;174(2):e69-73. doi: 10.1016/j.jss.2011.10.038. Epub 2011 Nov 19. J Surg Res. 2012. PMID: 22261589
-
Clinical findings of patients with pseudomyxoma peritonei of appendiceal origin undergoing Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).Updates Surg. 2020 Sep;72(3):923-924. doi: 10.1007/s13304-020-00842-2. Epub 2020 Jun 29. Updates Surg. 2020. PMID: 32602012 No abstract available.
-
[Treatment of pseudomyxoma peritonei is developing].Duodecim. 2010;126(14):1693-9. Duodecim. 2010. PMID: 20804088 Review. Finnish.
-
Peritoneal pseudomyxoma arising from the urachus.Surg Oncol. 2012 Mar;21(1):1-5. doi: 10.1016/j.suronc.2009.12.004. Epub 2010 Feb 26. Surg Oncol. 2012. PMID: 20189378 Review.
Cited by
-
Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.J Gastrointest Surg. 2020 Apr;24(4):899-906. doi: 10.1007/s11605-019-04239-4. Epub 2019 May 14. J Gastrointest Surg. 2020. PMID: 31090036
-
Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.Orphanet J Rare Dis. 2014 May 5;9:71. doi: 10.1186/1750-1172-9-71. Orphanet J Rare Dis. 2014. PMID: 24886459 Free PMC article. Review.
-
Bromelain and acetylcysteine (BromAc®): a novel approach to the treatment of mucinous tumours.Am J Cancer Res. 2023 Apr 15;13(4):1522-1532. eCollection 2023. Am J Cancer Res. 2023. PMID: 37168359 Free PMC article. Review.
-
Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei.Cancer Biol Med. 2024 Jul 18;21(7):586-605. doi: 10.20892/j.issn.2095-3941.2024.0109. Cancer Biol Med. 2024. PMID: 39026438 Free PMC article. Review.
-
Oral administration of bromelain and acetylcysteine in pseudomyxoma peritonei (PMP) caused by low-grade appendiceal mucinous neoplasm (LAMN): a case report.J Med Case Rep. 2023 Jun 29;17(1):297. doi: 10.1186/s13256-023-04024-7. J Med Case Rep. 2023. PMID: 37381056 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical